Asean Business logo
SPONSORED BYUOB logo
SUBSCRIBERS

Less than six months after Nasdaq debut, Malaysia’s Alps Group pivots to bridge biotech access gap

It is expanding into insurance and education to rebuild valuation and put advanced treatments within reach for more people

Tan Ai Leng
Published Mon, Apr 20, 2026 · 07:00 AM
    • Alps Group's Dr Tham Seng Kong says: "The challenge is no longer about developing technology, but ensuring that it can be used by the mass market. The problem is, most people cannot afford it."
    • Alps Group's Dr Tham Seng Kong says: "The challenge is no longer about developing technology, but ensuring that it can be used by the mass market. The problem is, most people cannot afford it." PHOTO: TAN AI LENG, BT

    DeeperDive is a beta AI feature. Refer to full articles for the facts.

    [KUALA LUMPUR] Less than six months after its debut on the Nasdaq, Malaysia’s Alps Group is shifting its focus from research to execution, expanding into insurance and education as it seeks to close critical gaps in access to advanced medical technologies.

    Alps’ push to build a full-stack ecosystem comes as it navigates the realities of being a newly listed biotech firm.

    According to US Securities and Exchange Commission filings and Nasdaq data, Alps Group is in the early stages of commercialisation, reporting 12-month trailing revenue of around US$3.7 million and has yet to achieve profitability.

    Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.

    Copyright SPH Media. All rights reserved.